scholarly article | Q13442814 |
P2093 | author name string | Steven D Leach | |
Smrita Sinha | |||
P2860 | cites work | Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. | Q38808099 |
p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. | Q38817859 | ||
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms | Q38905926 | ||
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. | Q38909479 | ||
NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. | Q38916311 | ||
The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice | Q38919135 | ||
Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity | Q38920277 | ||
Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. | Q39008845 | ||
miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. | Q39017335 | ||
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 | ||
Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma | Q41856856 | ||
MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes | Q42016960 | ||
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer | Q45339155 | ||
IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia | Q47098673 | ||
Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer. | Q53215067 | ||
Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. | Q53221266 | ||
SOX9 regulates ERBB signalling in pancreatic cancer development. | Q53229089 | ||
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer | Q60594558 | ||
Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis | Q24336049 | ||
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs | Q28214865 | ||
SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth | Q28258574 | ||
Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism | Q28834389 | ||
Pancreatic cancers require autophagy for tumor growth | Q29620331 | ||
Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma | Q30502257 | ||
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. | Q33858490 | ||
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma | Q33896442 | ||
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations | Q34017017 | ||
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy | Q34253198 | ||
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival | Q34269713 | ||
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma | Q35134601 | ||
Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation | Q35228755 | ||
Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. | Q35374899 | ||
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets | Q35487646 | ||
Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages | Q35687807 | ||
Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma | Q35748110 | ||
Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy | Q36000807 | ||
IL17 Functions through the Novel REG3β-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer | Q36296837 | ||
BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. | Q36319886 | ||
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. | Q36664869 | ||
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. | Q36803448 | ||
Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice | Q37008807 | ||
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. | Q37016288 | ||
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia | Q37040899 | ||
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma | Q37123636 | ||
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy | Q37127423 | ||
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism | Q37378754 | ||
Stromal biology and therapy in pancreatic cancer: a changing paradigm | Q38494338 | ||
Genomic analyses identify molecular subtypes of pancreatic cancer | Q38791499 | ||
P921 | main subject | pancreatic cancer | Q212961 |
P577 | publication date | 2016-07-21 | |
P1433 | published in | Current Opinion in Gastroenterology | Q15758708 |
P1476 | title | New insights in the development of pancreatic cancer |
Q60609732 | Commonly Used Pancreatic Stellate Cell Cultures Differ Phenotypically and in Their Interactions with Pancreatic Cancer Cells. |
Q91792642 | Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma |
Q38849004 | PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk. |
Q99403350 | Promising xenograft animal model recapitulating the features of human pancreatic cancer |
Q92076388 | Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy |
Search more.